This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

Andrea G. M. Scholes, PhD; Suzanne Hagan, BSc; Paul Hiscott, MRCPath; Bertil E. Damato, PhD; Ian Grierson, PhD

Arch Ophthalmol. 2001;119:373-377.

Objective  To determine whether expression of the epidermal growth factor receptor (EGFR) is of prognostic value in uveal melanoma.

Methods  Thirty consecutive patients treated for primary posterior uveal melanoma by enucleation or local resection were studied. Tumors were examined for EGFR and CD68 expression by immunohistochemistry on formalin-fixed, paraffin-embedded sections. Extracted DNA from paired frozen tumor and blood samples was examined for loss of heterozygosity on chromosome 3 using polymerase chain reaction–based microsatellite analysis. Immunoreactivity for EGFR was correlated with clinicopathological, chromosome 3, and follow-up data.

Results  Immunoreactivity for EGFR was observed in 7 (23%) of 30 uveal melanomas, but was restricted to solitary or small groups of cells with macrophage-like morphology. Immunoreactive cells were confirmed as macrophages using an antibody to the macrophage marker CD68. Chromosome 3 loss, epithelioid cells, and microvascular loops were detected in 17 (57%), 22 (73%) and 19 (63%) of the 30 tumors, respectively. Metastatic disease was detected in 5 patients (17%). No correlation was found between any of these variables and EGFR positivity.

Conclusions  The absence of EGFR immunoreactivity in tumor cells does not support the use of EGFR expression as a prognostic indicator in patients with uveal melanoma. Future EGFR studies in uveal melanoma should be interpreted with caution in view of our findings that tumor-associated macrophages can express this receptor.

From the Unit of Ophthalmology, Department of Medicine (Drs Scholes, Hiscott, and Grierson and Ms Hagan), and the Department of Pathology (Dr Hiscott), University of Liverpool, and the Ocular Oncology Service, St Paul's Eye Unit, Royal Liverpool University Hospital (Dr Damato), Liverpool, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors
Nakagawa et al.
Jpn J Clin Oncol 2009;39:116-123.
ABSTRACT | FULL TEXT